Ngā hua rapu - Giuseppe Favacchio
- E whakaatu ana i te 1 - 5 hua o te 5
-
1
Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in L... mā Marco Mirani, Giuseppe Favacchio, Flaminia Carrone, Nazarena Betella, Emilia Biamonte, Emanuela Morenghi, Gherardo Mazziotti, Andrea Lania
I whakaputaina 2020Carta -
2
-
3
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study mā Sara Piccini, Giuseppe Favacchio, Cristina Panico, Emanuela Morenghi, Franco Folli, Gherardo Mazziotti, Andrea Lania, Marco Mirani
I whakaputaina 2023Artigo -
4
Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review mā Cristina Panico, Benedetta Maria Bonora, Antonella Camera, Nino Cristiano Chilelli, Giuliana Da Prato, Giuseppe Favacchio, Valeria Grancini, Veronica Resi, Maurizio Rondinelli, Emanuela Zarra, Basilio Pintaudi
I whakaputaina 2023Revisão -
5
Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01) mā Cesare Berra, Maria Chiara Rossi, Marco Mirani, Daniela Ceccarelli Ceccarelli, Cristina Romano, L. Sassi, Elena Peretti, Giuseppe Favacchio, Ida Pastore, L. Folini, Giusi Graziano, Maria Elena Lunati, Sebastiano Bruno Solerte, Paolo Fiorina
I whakaputaina 2023Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Diabetes mellitus
Endocrinology
Internal medicine
Medicine
Type 2 diabetes
Glycated hemoglobin
Proportional hazards model
Retrospective cohort study
Agonist
Angiology
Anthropometry
Bioinformatics
Biology
Blood pressure
Body mass index
Cardiology
Comorbidity
Confidence interval
Coronavirus disease 2019 (COVID-19)
Dipeptidyl peptidase-4
Disease
Ejection fraction
Environmental health
Gastroenterology
Glucagon-like peptide 1 receptor
Glucagon-like peptide-1
Glycemic
Hazard ratio
Heart failure
Heart failure with preserved ejection fraction